1-833-ZEPOSIA

ZEPOSIA is a once-daily pill for adults with moderate to severe ulcerative colitis (UC).

Take as directed by your doctor if certain liver problems exist.

MenuClose

ZEPOSIA is a once-daily pill for adults with moderate to severe ulcerative colitis (UC).

Take as directed by your doctor if certain liver problems exist.

What is ZEPOSIA?

Get to know more about ZEPOSIA, a once-daily pill for UC, the results people saw in clinical studies, and how it could be the right next step for you.

ZEPOSIA® a proven UC treatment icon

Lasting remission

In clinical studies, people taking ZEPOSIA achieved lasting remission (fewer symptoms and reduced inflammation seen during a colonoscopy at 1 year).*

Magnifying glass icon

UC relief without steroids

ZEPOSIA is an advanced once-daily pill you can take without first having to try injections or infusions (biologics)—and it can provide UC relief without having to take steroids.

stopwatch icon

Early symptom relief

With ZEPOSIA, you can experience reduced rectal bleeding and fewer trips to the bathroom in as early as 2 weeks.

  • 37% achieved remission vs 19% on placebo. Reduces symptoms of rectal bleeding and stool frequency. Reduced inflammation representing mild or inactive disease in the colon.
  • 32% of patients achieved steroid-free remission at 1 year vs 17% on placebo.
  • Advanced therapies=S1P receptor modulators, biologics, and JAK inhibitors.
colon icon

Reduced intestinal inflammation

ZEPOSIA can help with intestinal healing by visibly reducing inflammation on and below the surface of the colon lining.§

Shield with exclamation point icon

A well-established safety profile across multiple conditions

ZEPOSIA was studied in 4 clinical studies, across 2 conditions.||

ZEPOSIA® Co-pay Program icon

Support and savings

Eligible, commercially insured patients may pay as little as $0 per month for ZEPOSIA with a co-pay savings offer. Additional eligibility requirements and terms & conditions apply. Please click here for more information.

  • 30% of patients achieved this result at 1 year, compared to 14% on placebo. Impact of intestinal healing on UC progression and long-term outcomes was not studied.
  • ZEPOSIA was studied in ulcerative colitis and multiple sclerosis in over 1,300 patients.
Gastroenterologist Dr. Lee and real ZEPOSIA® patient Rosie Gastroenterologist Dr. Lee and real ZEPOSIA® patient Rosie
Quotation mark icon

A lot of patients normalize their symptoms and change their lives to accommodate them. That’s not the goal—the goal of treatment is remission.

—Dr. Lee
Real gastroenterologist, paid consultant of Bristol Myers Squibb.

Dr. Lee and his patient, Rosie, used open communication to find an option that worked for her. Click here to see how.

Watch the ZEPOSIA TV commercial

ZEPOSIA® TV commercial video thumbnail

2084-US-2301365 01/24